SOPHiA GENETICS SA (NASDAQ:SOPH) Sees Significant Decline in Short Interest

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a significant decline in short interest in the month of September. As of September 15th, there was short interest totalling 18,900 shares, a decline of 52.0% from the August 31st total of 39,400 shares. Based on an average daily volume of 61,900 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.0% of the company’s shares are short sold.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Guggenheim started coverage on shares of SOPHiA GENETICS in a research report on Thursday, June 27th. They set a “buy” rating and a $6.00 price objective for the company. Royal Bank of Canada lowered their target price on SOPHiA GENETICS from $8.00 to $7.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Finally, Morgan Stanley lowered SOPHiA GENETICS from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $10.00 to $5.00 in a report on Wednesday, August 7th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Banque Cantonale Vaudoise raised its stake in shares of SOPHiA GENETICS by 300.0% during the 2nd quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock worth $55,000 after purchasing an additional 9,000 shares in the last quarter. Federated Hermes Inc. increased its holdings in SOPHiA GENETICS by 57.5% during the second quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock worth $289,000 after buying an additional 23,000 shares during the last quarter. Moloney Securities Asset Management LLC increased its holdings in SOPHiA GENETICS by 111.4% during the first quarter. Moloney Securities Asset Management LLC now owns 178,000 shares of the company’s stock worth $878,000 after buying an additional 93,800 shares during the last quarter. Edmond DE Rothschild Holding S.A. raised its position in SOPHiA GENETICS by 5.0% during the first quarter. Edmond DE Rothschild Holding S.A. now owns 203,334 shares of the company’s stock worth $1,002,000 after acquiring an additional 9,700 shares in the last quarter. Finally, Essex Investment Management Co. LLC lifted its stake in SOPHiA GENETICS by 112.1% in the first quarter. Essex Investment Management Co. LLC now owns 262,834 shares of the company’s stock valued at $1,296,000 after acquiring an additional 138,933 shares during the last quarter. 31.59% of the stock is owned by institutional investors and hedge funds.

SOPHiA GENETICS Stock Down 2.6 %

Shares of SOPH stock traded down $0.10 during trading on Friday, reaching $3.73. The company’s stock had a trading volume of 6,733 shares, compared to its average volume of 74,447. SOPHiA GENETICS has a one year low of $2.41 and a one year high of $7.37. The business has a fifty day moving average price of $3.91 and a 200-day moving average price of $4.50. The company has a market cap of $243.87 million, a price-to-earnings ratio of -3.33 and a beta of 1.04. The company has a quick ratio of 4.17, a current ratio of 4.40 and a debt-to-equity ratio of 0.11.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.05. The firm had revenue of $15.81 million for the quarter, compared to analysts’ expectations of $17.58 million. SOPHiA GENETICS had a negative net margin of 102.84% and a negative return on equity of 47.40%. During the same period in the previous year, the firm posted ($0.33) EPS. Analysts anticipate that SOPHiA GENETICS will post -0.95 earnings per share for the current year.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.